GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Harmony Biosciences Holdings HRMY · USD

Health Care · US listing · 🇺🇸 United States

Compare

33.78

+2.02%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$868.5m

FY2018FY2025

Net income

$158.7m

FY2018FY2025

Free cash flow

$347.9m

FY2018FY2025

Shareholders' equity

$870.2m

FY2018FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue$868.5m$714.7m$582.0m$437.9m$305.4m$159.7m$6.0m—
Gross profit$670.1m$557.9m$460.8m$354.4m$249.9m$132.0m$4.4m−$184,000
Research and development$189.6m$145.8m$76.1m$70.9m$30.4m$19.4m$69.6m$12.4m
Operating income$208.5m$190.8m$192.0m$120.2m$87.5m$17.0m−$145.9m−$41.4m
Net income$158.7m$145.5m$128.9m$181.5m$34.6m−$36.9m−$152.0m−$39.9m
Diluted earnings per share2.702.502.192.940.57-0.65-2.75-0.81

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Total assets$1.27bn$999.2m$811.4m$673.9m$433.4m$427.1m$106.7m$89.3m
Cash and short-term investments$775.3m$467.2m$353.5m$323.1m$234.3m$228.6m$24.5m$83.5m
Total liabilities$401.4m$340.0m$344.5m$271.0m$246.9m$329.9m$118.3m$7.8m
Debt$230.6m$179.3m$193.6m$191.6m$192.0m$194.3m$97.9m—
Shareholders' equity$870.2m$659.2m$467.0m$402.8m$186.5m$97.2m−$11.6m$81.5m
Shares outstanding59m58m59m62m60m57m55m49m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations$348.2m$219.8m$219.4m$144.5m$98.6m−$3.0m−$75.4m−$38.8m
Capital spending−$310,000−$1.2m−$312,000−$172,000−$298,000−$2.0m−$149,000−$1.3m
Free cash flow$347.9m$218.7m$219.1m$144.3m$98.3m−$5.0m−$75.6m−$40.1m
Dividends paid——−$5.1m——−$200.3m−$143.8m—

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$261.3m$215.4m$243.8m$239.5m$200.5m$184.7m$201.3m$186.0m
Gross profit$198.1m$170.9m$175.2m$179.8m$162.3m$152.7m$146.9m$143.3m
Operating income$89.3m$37.3m$38.6m$65.5m$48.2m$56.2m$55.7m$61.7m
Net income$75.4m$32.5m$22.5m$50.9m$39.8m$45.6m$49.5m$46.1m
Diluted earnings per share1.280.550.380.870.680.780.850.79
Cash from operations$92.0m$27.0m$126.0m$108.0m$79.0m$33.0m$75.0m$70.0m
Total assets$1.37bn$1.27bn$1.27bn$1.21bn$1.11bn$1.06bn$999.2m$928.1m
Cash and short-term investments$667.8m$640.9m$775.3m$672.6m$565.3m$507.0m$467.2m$410.5m
Debt$154.0m$202.0m$230.6m$169.3m$172.9m$176.8m$180.6m$184.4m
Shareholders' equity$999.2m$910.3m$870.2m$835.1m$773.1m$720.5m$659.2m$596.8m

Financial ratios

Data as of 29 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin77.2%78.1%79.2%80.9%81.8%82.6%
Operating margin26.5%29.3%33.9%28.2%20.2%-5.5%
Net margin18.3%20.4%22.1%41.4%11.3%-23.1%
Return on equity18.2%22.1%27.6%45.0%18.5%-38.0%
Return on assets12.5%14.6%15.9%26.9%8.0%-8.7%
Free cash flow yield15.4%9.9%9.7%6.1%4.3%-0.0%
Revenue growth21.5%22.8%32.9%43.4%91.2%2564.6%
Earnings growth9.1%12.9%-29.0%424.5%-193.6%-75.7%
Current ratio3.60x3.31x2.75x5.07x5.29x1.95x
Debt to equity0.26x0.27x0.41x0.48x1.04x2.00x
Equity ratio68.4%66.0%57.6%59.8%43.0%22.8%
Interest coverage15.68x11.96x8.30x6.57x2.55x-0.31x
R&D as a share of sales21.8%20.4%13.1%16.2%9.9%12.2%
Buybacks as a share of market value-0.8%1.1%4.5%-2.2%-6.0%-2.9%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue25.6%40.3%—
Operating income20.2%65.1%—
Net income-4.4%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin77.6%78.5%79.0%—
Operating margin25.2%27.3%26.6%—
Net margin19.2%23.6%20.0%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings13.813.814.818.774.3-55.7
Price to sales2.52.83.37.88.412.9

Market value over time

31 Aug 2020 to 28 Oct 2026, in USD

$283.4m$2.26bn

Share price return

Finished calendar years

202520242023202220212020
Return12%0%-39%34%13%-2%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.